

Poster 2105

INTRODUCTION

- Polyomavirus-associated nephropathy (BKVAN) is one of the serious causes of allograft dysfunction and allograft loss in kidney transplant (KT) patients.
- Most of the patients were diagnosed with BKVAN within the first year after transplantation but some more cases of **BKVAN** occur later.
- A study focused on the differentiation between early and late-onset BKVAN is needed.

METHODS

- A retrospective cohort study
- Ramathibodi Hospital, Bangkok, Thailand
- January 2010 December 2020
- The incidence of early-onset (diagnosed within 1 year) and late-onset (diagnosed after 1 year) BKVAN, as well as composite kidney allograft outcomes, were compared.
- Definitions
- **Probable BKVAN:** BK viremia > 10³ copies/mL sustained in < 3 weeks
- **Presumptive BKVAN:** BK viremia > 10⁴ copies/mL.
- **Biopsy-proven BKVAN:** viral cytopathic change, interstitial infiltration, tubulitis with positive SV40 staining on kidney allograft biopsy.

Early-onset and Late-onset BK Polyomavirus-associated Nephropathy: A 10-year Retrospective Analysis Vichitra Thiandech, MD¹, Surasak Kantachuvesiri, MD^{1,2}, Jackrapong Bruminhent, MD^{2,3} ¹Division of Nephrology, Department of Medicine, ²Ramathibodi Excellence Center for Organ Transplantation,

³Division of Infectious Diseases, Department of Medicine


Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

RESULTS

- From 1032 KT recipients, 645 (62.5%) were screened for BK viral infection. BKVAN was diagnosed in 83 (12.8%) patients.
- Of those, 46 (55.4%) and 37 (44.6%) were diagnosed with early-onset and late-onset BKVAN, respectively.
- Composite kidney allograft outcomes of GFR decline≥ 40% from baseline, graft loss or death were greater in early-onset **BKVAN** compared to late-onset **BKVAN** (7.5 vs 5.52 per 1000 person-months; hazard ratio 0.47; 95%CI, 0.23-0.95; P=0.037).
- In multivariate analysis, female gender and living-related kidney transplantation (LRKT) were independently associated with lateonset BKVAN compared to early-onset **BKVAN**.
- The more advanced the BKVAN diagnosis, the worse the allograft outcome occurs, even with optimizing immunosuppressive drugs and adjunctive therapy.

REFERENCES

- 1. Hirsch HH, et al. N Engl J Med. 2002 Aug 15;347(7):488-96.
- 2. Yooprasert P, et al. Transplant Proc. 2018 Jan-Feb;50(1):130-136.
- 3. Skulratanasak P, et al. BK Virus Infection in Thai Kidney Transplant Recipients: A Single-Center Experience. Transplant Proc. 2018 May;50(4):1077-1079.



CONCLUSIONS

- BKVAN could occur late after one-year post-transplantation, although relatively better composite kidney outcomes were observed compared to earlyonset BKVAN.
- Female individuals who underwent living-related KT should be considered for BK virus preemptive monitoring beyond one year to detect this lateonset BK virus infection.

CONTACT

Jackrapong Bruminhent, MD

Division of Infectious Diseases, Department of Medicine, Ramathibodi Hospital, Mahidol University 270 Rama VI Rd, Ratchathewi, Bangkok, 10400, Thailand Email: jackrapong.brm@mahidol.ac.th

Age, ye

Gende

Episod

• First Retra

Type of

DDK. LRK[®]

Donor

AKI do

HLA M 0-3 N

• 4-6 N

PRA, n

0-10%

11-50

Cold isc (IQR)

Delayed

Inductio

No

ATG Anti

Type of

Biop

month Immur

Tacro Cycl

Peak pla cps/ml



Table Baseline Characteristics

Variables	Early-onset BKVAN	Late- onset BKVAN	P-value
	(N=46)	(N=37)	
ar, mean± SD	44.9 ± 12.1	42.1 ± 14.8	0.350
, n (%)			
le	8 (17.4)	13 (35.1)	0.065
es of transplantation, n(%)			
episode	43 (93.5)	36 (97.3)	0.625
Insplantation	3 (6.5)	1 (2.7)	
transplantation, n(%)			
	35 (76.1)	16 (43.2)	0.002
		. ,	0.002
	11 (23.9)	21 (56.8)	
age, year, mean ± SD	40.9 ± 16.6	36.8 ± 11.0	0.208
nor, n (%)	21 ± 45.7	16 ± 43.2	0.826
smatch, n(%)			
IM	37 (80.3)	28 (75.7)	0.601
IM	9 (19.57)	9 (24.3)	
(%)	· · · ·		
() /o	39 (84.8)	31 (83.8)	0.297
° 1%	3 (6.5)	0 (0)	
	4 (8.7)	6 (16.2)	
chemic time, min, median	945 (303 - 1173)	40 (20- 1045)	0.021
d graft function, n(%)	15 (32.6)	6 (16.2)	0.088
on, n (%)			
	12 (26.1)	17 (46.0)	0.189
	5 (10.9)	3 (8.1)	
L2	29 (63.0)	17 (46.0)	
BKVAN, n (%)			
able/Presumptive	23 (50.0)	11 (29.7)	0.062
-	, , ,	. ,	0.002
sy-proven	23 (50.0)	26 (70.3)	
om KT to BKVAN diagnosis, median (IQR)	5.4 (3.3, 7.8)	23.5 (19.3, 47.8)	< 0.001
osuppressive drug level,			
mean ± SD	6.8 ± 1.9	6.13 ± 1.98	0.169
olimus			
osporin A	150.1 ± 69.2	118.7 ± 38.8	0.468
	1 / / 1 0 /	101 577	
asma BK VL at diagnosis, median (IQR)	144,134	424.577	0.545
	(32,613 - 10 ⁶)	(93,517-848,816)	